/stocks — the workspaceLOADING

KAPA · All filings · Read this filing

What changed 10-Q

Item 5. Other Information

2025-05-14 compared with 2024-11-14 · 26 added, 52 removed, 13 unchanged (86% of the section changed)

Other Information.

During the period ended September 30, 2024, none of our

During the period ended March 31, 2025, none of our

directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading

5 unchanged sentences

Form of Representative’s Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1, filed on August 16, 2024)

Bioassay Services Agreement, dated September 20, 2024, between the Company and PreCheck (incorporated by reference to Exhibit 10.1 to the Company’s current Report on Form 8-K filed on September 24, 2024).

Form of Advertising Services Agreement, dated September 23, 2024, between the Company and CEO.CA Technologies, Inc.

(incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 27, 2024).

Form of Advisory & Consulting Agreement, dated September 23, 2024, between the Company and Belair Capital Advisors Inc.

(incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on September 27, 2024).

Consulting Agreement, dated October 1, 2024, between Kairos Pharma, Ltd, Cross Current Capital LLC and Alan Masley (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 4, 2024).

Purchase Agreement, dated November 12, 2024, by and between Kairos Pharma, Ltd.

and Helena Global Investment Opportunities I Ltd.

Second Conversion Agreement, dated November 13, 2024, by and between Kairos Pharma, Ltd.

and Cedars-Sinai Medical Center.

Third Amendment to Exclusive License Agreement (Cancer Autoimmune), dated November 13, 2024, by and between Kairos Pharma, Ltd.

and Cedars-Sinai Medical Center.

Fourth Amendment to Exclusive License Agreement (Depletion of DNA), dated November 13, 2024, by and between Kairos Pharma, Ltd.

and Cedars-Sinai Medical Center and Enviro Therapeutics, Inc,

Third Amendment to Exclusive License Agreement (Fibrosis), dated November 13, 2024, by and between Kairos Pharma, Ltd.

and Cedars-Sinai Medical Center.

Third Amendment to Exclusive License Agreement (RelA of NF-kB), dated November 13, 2024, by and between Kairos Pharma, Ltd.

and Cedars-Sinai Medical Center.

Fourth Amendment to Exclusive License Agreement (Sensitization of Solid Tumors), dated November 13, 2024, by and between Enviro Therapeutics Inc.

and Cedars-Sinai Medical Center.

Form of the Amendment No.1 to the Employment Agreement by and between Kairos Pharma, Ltd and Doug Samuelson

Form of the Amendment No.1 to the Employment Agreement by and between Kairos Pharma, Ltd and Dr.

Ramachandran Murali

Form of the Amendment No.1 to the Employment Agreement by and between Kairos Pharma, Ltd and Dr.

Neil Bhowmick

Form of Amendment No.

1 to Employment Agreement by and between Kairos Pharma, Ltd.

Certification

of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002.

Certification

of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002.

Certification

of Principal Executive Officer Pursuant to 18 U.S.C.

Section 1350, as Adopted Pursuant to Section

906 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Executive Officer Pursuant to 18 U.S.C.

Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Financial Officer Pursuant to 18 U.S.C.

Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

XBRL Instance Document—the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within

the Inline XBRL document.

XBRL Taxonomy Extension Schema.

XBRL Taxonomy Extension Calculation Linkbase.

XBRL Taxonomy Extension Definition Linkbase.

XBRL Taxonomy Extension Label Linkbase.

XBRL Taxonomy Extension Presentation Linkbase.

Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).

Inline XBRL Instance Document-the

instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.

Inline XBRL Taxonomy Extension

Inline XBRL Taxonomy Extension

Calculation Linkbase.

Inline XBRL Taxonomy Extension

Definition Linkbase.

Inline XBRL Taxonomy Extension

Label Linkbase.

Inline XBRL Taxonomy Extension

Presentation Linkbase.

Cover Page Interactive Data

File (embedded within the Inline XBRL document and contained in Exhibit 101).

* Filed herewith.

** Furnished herewith.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned, thereunto duly authorized.

November 14, 2024

Executive Officer and Chairman of the Board of Directors (principal executive officer)

Pursuant to the requirements of the Securities Exchange

Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

KAIROS PHARMA, LTD.

Chief Executive Officer and Chairman of the Board of Directors (principal

executive officer)

/s/ Douglas Samuelson

Douglas Samuelson

Financial Officer

Financial and Accounting Officer)

Chief Financial Officer

(Principal Financial and Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.